MADRIGAL PHARMACEUTICALS, INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | 442 | $273.41 | $120,847 | 5,058 | Jan 17, 2025 |
| Taub Rebecca | Pres., R&D, and CMO | Sale | 1,689 | $273.41 | $461,789 | 457,310 | Jan 17, 2025 |
| CRAVES FRED B | — | Sale | 3,080 | $315.21 | $970,847 | 11,520 | Dec 3, 2024 |
| CRAVES FRED B | — | Sale | 2,200 | $350.08 | $770,176 | 15,800 | Nov 25, 2024 |
| Huntsman Carole | Chief Commercial Officer | Sale | 688 | $316.92 | $218,041 | 10,785 | Nov 21, 2024 |
| Levy Richard S | — | Sale | 5,000 | $350.00 | $1,750,000 | 11,012 | Nov 7, 2024 |
| Levy Richard S | — | Sale | 300 | $304.29 | $91,287 | 11,012 | Nov 1, 2024 |
| CRAVES FRED B | — | Gift | 15,000 | — | — | 360,076 | Sep 13, 2024 |
| Sibold William John | President and CEO | Sale | 6,363 | $243.83 | $1,551,490 | 55,887 | Sep 9, 2024 |
| Kelley Shannon T | General Counsel | Award / Grant | 5,215 | — | — | 7,982 | Aug 15, 2024 |
| CRAVES FRED B | — | Award / Grant | 714 | — | — | 375,076 | Jun 25, 2024 |
| BATE KENNETH | — | Award / Grant | 714 | — | — | 1,912 | Jun 25, 2024 |
| Daly James M | — | Award / Grant | 714 | — | — | 1,912 | Jun 25, 2024 |
| Levy Richard S | — | Award / Grant | 714 | — | — | 11,012 | Jun 25, 2024 |
| FRIEDMAN PAUL A | — | Award / Grant | 714 | — | — | 186,449 | Jun 25, 2024 |
| Baker Bros. Advisors (GP) LLC | — | Award / Grant | 1,428 | — | — | 1,794,831 | Jun 25, 2024 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Option Exercise | 1,900 | $87.09 | $165,471 | 7,400 | Jun 14, 2024 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Option Exercise | 2,000 | $87.92 | $175,840 | 7,500 | Jun 12, 2024 |
| CRAVES FRED B | — | Gift | 45,852 | — | — | 11,210 | Jun 11, 2024 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | 1,036 | $231.34 | $239,668 | 5,500 | May 21, 2024 |
| CRAVES FRED B | — | Sale | 2,190 | $213.85 | $468,332 | 418,462 | May 14, 2024 |
| Taub Rebecca | Pres., R&D, and CMO | Sale | 200 | $248.58 | $49,716 | 458,999 | Apr 8, 2024 |
| FRIEDMAN PAUL A | — | Option Exercise | 26,270 | $9.45 | $248,251 | 212,005 | Apr 8, 2024 |
| Taub Rebecca | Pres., R&D, and CMO | Sale | 700 | $241.14 | $168,798 | 484,162 | Apr 5, 2024 |
| FRIEDMAN PAUL A | — | Sale | 2,549 | $245.14 | $624,862 | 188,230 | Apr 4, 2024 |
| Daly James M | — | Option Exercise | 1,577 | $105.08 | $165,711 | 22,775 | Apr 1, 2024 |
| Levy Richard S | — | Sale | 300 | $267.07 | $80,121 | 10,298 | Apr 1, 2024 |
| BATE KENNETH | — | Sale | 700 | $265.36 | $185,752 | 1,472 | Apr 1, 2024 |
| Huntsman Carole | Chief Commercial Officer | Award / Grant | 3,639 | — | — | 11,473 | Jan 23, 2024 |
| Taub Rebecca | Pres., R&D, and CMO | Award / Grant | 5,786 | — | — | 20,787 | Jan 23, 2024 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Award / Grant | 1,419 | — | — | 6,536 | Jan 23, 2024 |
| Howarth Alex G. | Chief Financial Officer | Award / Grant | 4,803 | — | — | 18,737 | Jan 23, 2024 |
| Lynch Brian Joseph | SVP and General Counsel | Award / Grant | 3,639 | — | — | 17,691 | Jan 23, 2024 |
| Sibold William John | President and CEO | Award / Grant | 12,250 | — | — | 62,250 | Jan 23, 2024 |
| Lynch Brian Joseph | SVP and General Counsel | Tax Withholding | 949 | $243.92 | $231,480 | 14,052 | Jan 16, 2024 |
| Taub Rebecca | Pres., R&D, and CMO | Tax Withholding | 1,546 | $243.92 | $377,100 | 15,001 | Jan 16, 2024 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Tax Withholding | 550 | $243.92 | $134,156 | 5,117 | Jan 16, 2024 |
| Howarth Alex G. | Chief Financial Officer | Tax Withholding | 1,067 | $243.92 | $260,263 | 13,934 | Jan 16, 2024 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Option Exercise | 2,000 | $87.92 | $175,840 | 7,667 | Dec 14, 2023 |
| BAKER BROS. ADVISORS LP | — | Purchase | 10,894 | $217.52 | $2,369,663 | 1,720,287 | Dec 13, 2023 |
| 667, L.P. | — | Purchase | 93 | $209.77 | $19,509 | 1,669,016 | Dec 12, 2023 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | 800 | $219.00 | $175,200 | 5,667 | Dec 12, 2023 |
| CRAVES FRED B | — | Other | 1,510,521 | — | — | — | Dec 7, 2023 |
| Lynch Brian Joseph | SVP and General Counsel | Sale | 1,000 | $227.33 | $227,330 | 15,001 | Dec 4, 2023 |
| Lynch Brian Joseph | SVP and General Counsel | Sale | 1,000 | $206.73 | $206,730 | 15,001 | Nov 29, 2023 |
| BAKER JULIAN | — | Purchase | 2,124 | $187.24 | $397,698 | 1,612,339 | Nov 21, 2023 |
| Huntsman Carole | Chief Commercial Officer | Award / Grant | 7,834 | — | — | 7,834 | Nov 20, 2023 |
| Baker Brothers Life Sciences LP | — | Purchase | 461 | $171.79 | $79,195 | 1,547,989 | Nov 17, 2023 |
| BAKER JULIAN | — | Purchase | 14,018 | $161.97 | $2,270,495 | 1,545,775 | Nov 14, 2023 |
| BAKER FELIX | — | Purchase | 6,022 | $152.48 | $918,235 | 1,475,058 | Nov 14, 2023 |